ALLO - Allogene Therapeutics

-

$undefined

N/A

(N/A)

Allogene Therapeutics NasdaqGS:ALLO Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Location: 210 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://allogene.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

66.98M

Cash

280M

Avg Qtr Burn

-49.33M

Short % of Float

17.48%

Insider Ownership

17.21%

Institutional Own.

81.20%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Cemacabtagene Ansegedleucel (cema-cel) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Update

ALLO-316 (CD70) Details
Clear cell renal cell carcinoma (ccRCC)

Phase 1b

Data readout

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

Phase 1

Update

ALLO-605 (BCMA) Details
Multiple myeloma, Cancer

Phase 1

Update

Phase 1

Initiation